key: cord-0905493-dktzqt1a
authors: Seneviratne, Suranjith L; Yasawardene, Pamodh; Wijerathne, Widuranga; Somawardana, Buddhika
title: COVID-19 vaccination in cancer patients: a narrative review
date: 2022-03-22
journal: J Int Med Res
DOI: 10.1177/03000605221086155
sha: 57fdb526cd1782f6f6ef5e96c2043cda52f3fb25
doc_id: 905493
cord_uid: dktzqt1a

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected over 220 million individuals worldwide, and has been shown to cause increased disease severity and mortality in patients with active cancer versus healthy individuals. Vaccination is important in reducing COVID-19-associated morbidity and mortality. Thus, the aim of this article was to review the existing knowledge on effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer. Fifty-four articles were included following a search of PubMed and Google Scholar databases for studies published between January 2020 and September 2021 that investigated humoral and cell-mediated immune responses following COVID-19 vaccination in patients with cancer. Immunogenicity of vaccines was found to be lower in patients with cancer versus healthy individuals, and humoral immune responses were inferior in those with haematological versus solid cancers. Patient-, disease-, and treatment-related factors associated with poorer vaccine responses should be identified and corrected or mitigated when possible. Consideration should be given to offering patients with cancer second doses of COVID vaccine at shorter intervals than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. Vaccine adverse effect profiles are comparable between patients with cancer and healthy individuals.

Coronavirus disease 2019 (COVID- 19) , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 220 million individuals worldwide since it was first reported in December 2019. 1 In addition to its effects on the respiratory system, COVID-19 has been shown to cause a myriad of manifestations in other organ systems, [2] [3] [4] [5] and to cause increased disease severity and mortality in patients with active cancer. [6] [7] [8] [9] In addition to several proposed novel treatment strategies, 10, 11 vaccination is an important preventive strategy for reducing COVID-19-associated morbidity and mortality. 12 However, patients with cancer may have a poorer response to COVID-19 vaccination compared with healthy individuals. The emergence of SARS-CoV-2 variants has led to further changes in disease manifestations and the effectiveness of vaccines. 13 Shortened vaccination schedules and provision of a third dose of vaccines has been proposed for patients with cancer. In the present article, existing knowledge (as at the end of September 2021) on the effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer is discussed.

The currently available COVID-19 vaccines are efficacious at protecting against severe infection, hospitalization and death, but are less effective at providing complete protection against infection. 14 Fully vaccinated people are much less likely to suffer from severe SARS-CoV-2 infection. Following the first dose of a COVID-19 vaccine in a healthy individual, both antibody and cellular immune responses occur. 15 The emergence of SARS-CoV-2 variants with spike mutations that impact antibody recognition threatens the success of SARS-CoV-2 vaccine programs. 16 A single dose of the BNT162b2/Pfizer or ChAdOx1 nCoV-19 (Astra-Zeneca) vaccine provides around 30 percent effectiveness against the currently prevailing Delta variant. 17 However, following the second vaccine dose, an increase in both antibody and cellular immune responses are observed and the effectiveness of the vaccines increases to over 67-88% at two weeks post-second dose of the vaccine. 17 

The immunogenicity and effectiveness of vaccines in patients with solid and haematological cancers have been assessed in different studies. The antibody response rate to the trivalent inactivated influenza vaccine in adult patients with lung cancer was found to be 78%, 4-6 weeks after a single dose, which is comparable to findings in healthy volunteers; 18 In another study, vaccine effectiveness was reported to be 21% and 20%, respectively, against laboratoryconfirmed influenza infection or hospitalization, in patients with solid and haematological cancer. 19 Of note, vaccine effectiveness was significantly higher among patients with solid (25%) compared with haematological (8%) cancers, but no significant difference was seen in patients with solid tumours either receiving or not receiving active chemotherapy. 19 In a prospective study from the Roswell Park Cancer Institute among patients with colorectal cancer receiving the trivalent influenza vaccine, the immune response rate was 71%, with no significant difference between patients receiving or not receiving active chemotherapy. 20 A study involving paediatric patients with solid and haematological cancer, vaccinated with two doses of live-attenuated varicella vaccine, found a seroconversion rate of 19% and 94% after the first and second doses, respectively, with a significant rise in antibody titres following the second dose. 21 Among paediatric patients with solid and haematological (lymphoma) cancers, receiving a double dose of inactivated hepatitis A vaccine, the seroconversion rate was 60% and 74% following the first and second doses, with no significant difference in seropositivity between patients with solid tumours or lymphoma. 22 A randomized controlled trial of a 13-valent pneumococcal conjugate vaccine in patients with gastric and colorectal cancer, to assess immunogenicity at different time intervals between receiving the vaccine and initiation of chemotherapy, revealed no significant difference in antibody responses between those receiving the vaccine on day 1 of chemotherapy and those who received the vaccine 2 weeks prior to chemotherapy initiation. 23 These findings suggest that cancer patients can mount a reasonable response to vaccination despite being on chemotherapy. However, those with certain haematological malignancies may have a blunted and heterogenous vaccination response than those with solid malignancies.

To review existing knowledge on the effectiveness, immunogenicity and safety of COVID-19 vaccines in patients with cancer, the PubMed and Google Scholar databases were searched for articles published between January 2020 and September 2021, using the search terms " ( PubMed and "COVID AND vaccine AND cancer" and "COVID AND vaccine AND haematological malignancy" in Google Scholar. Retrospective and prospective observational and cohort studies describing humoral and cell-mediated immune responses following COVID-19 vaccination in patients with cancer, with or without a control group comparison, were included following review of abstracts and full text after eliminating duplicates and non-English articles (Figure 1 ).

A total of 54 studies on COVID-19 vaccines in patients with cancer were included in this review. Patients with cancer showed reduced immunogenicity in response to COVID-19 vaccines in terms of both humoral and cell-mediated immune responses. The important immune response findings, following the use of available COVID-19 vaccines in patients with solid and/or haematological cancer, are summarised in Table 1 .

A large study in Lithuania found significantly lower anti-S1 IgG antibody titres in 315 adult patients with haematological malignancies compared with 67 age-matched healthy controls after full (double-dose) vaccination with BNT162b2/Pfizer vaccine. 53 Seroconversion rates and neutralization capacity are reduced in cancer patients compared to healthy controls. 33 In a US study of 551 patients with haematological cancer, seroconversion rates after first and second doses of the BNT162b2/Pfizer and mRNA-1273/Moderna vaccines were 52% and 69%, respectively. The neutralizing capacity in these patients was 26% and 43% after the first and second doses, which was considerably lower than in healthy controls (93% and 100%, respectively). 33 Low seroconversion rates in patients with cancer have been reported after the ChAdOx1 (Oxford-AstraZeneca), 35, 36, 58, 71, 73 Janssen Ad26. COV2.S, 37, 56, 74 BBIBP CorV (Sinopharm), 27 and CoronaVac (Sinovac Life Sciences, Beijing, China) vaccines. 46 In a study of 1 495 patients with haematological cancer, there was a significantly higher likelihood of an immune response following full (double-dose) vaccination with mRNA-1273/Moderna compared with the BNT162b2/Pfizer vaccine. 40 The authors speculated that this may be due to the larger dose of spike protein encoding mRNA (100 mg in the mRNA-1273/ Moderna vaccine versus 30 mg in the BNT162b2/Pfizer vaccine), or differences in mRNA sequence or composition, host cell penetrance, and dosing schedules. 40 A higher antibody titre following double-dose vaccination with mRNA-1273/Moderna compared with BNT162b2/Pfizer vaccines was also seen among 96 patients with multiple myeloma. 68 Among 551 patients with haematological malignancies, significantly higher antibody titres were observed after double-dose vaccination with mRNA-1273/Moderna compared with the BNT162b2/Pfizer vaccine, however, seropositivity rates were similar. 33 In 200 patients with solid and haematological malignancies, the Janssen Ad26.COV2.S (viral vector) vaccine was associated with lower antibody titres compared with the BNT162b2/Pfizer and mRNA-1273/ Moderna mRNA vaccines. 74 Among 129 patients with lymphoma, significantly higher antibody titres were observed following the BNT162b2/Pfizer compared with ChAdOx1 (Oxford-AstraZeneca) vaccine, after both the first and second doses. 49 However, other studies have reported no differences in seroconversion rates between the BNT162b2/Pfizer and mRNA-1273/ Moderna vaccines, 76 or in the magnitude of antibody response between the BNT162b2/Pfizer and ChAdOx1 (Oxford-AstraZeneca) vaccines. 58, 71 The magnitude of the antibody response following vaccination has been shown to differ between solid and haematological cancers. Antibody titres, seroconversion rates and neutralization capacity are lower in patients with haematological malignancy versus those with solid cancers. 24, 27, 34, 55, 67, 74 This is observed with the mRNA-based BNT162b2/Pfizer and mRNA-1273/ Moderna vaccines, 24, 34, 55, 67, 74 as well as the ChAdOx1 (Oxford-AstraZeneca), 67 Janssen Ad26.COV2.S, 67, 74 and BBIBP CorV (Sinopharm) vaccines. 27 A small study of 36 patients from Italy with solid and haematological malignancies found that cancer type (solid versus haematological) was not associated with median antibody levels. However, the study focused on older patients with cancer (aged !80 years), and this may have accounted for the finding. 44 The antibody response appears to be associated with treatment-, patient-, and disease-related factors. Among patients with haematological malignancies, treatment with anti-CD20 therapy (rituximab, ofatumumab, obinutuzumab, ocrelizumab, and veltuzumab), anti-CD38 therapy (daratumumab and isatuximab) and Bruton's tyrosine kinase inhibitors (BTKi; e.g., ibrutinib, acalabrutinib and zanubrutinib), B-cell maturation antigen (BCMA) targeted therapy, including bispecific T-cell engager and chimeric receptor antigen T-cell (CAR-T) therapy, kinase inhibitors (ruxolitinib), B-cell lymphoma-2 (BCL2) inhibitors (venetoclax) and hydroxycarbamide, have all been shown to be associated with poorer antibody responses, hence leaving the patient largely unprotected. [32] [33] [34] 36, 37, 42, 53, 56, 58, 59, 70, 75, 76 The timing of vaccination in relation to these therapies may be important, as vaccination at a shorter interval from anti-CD20 antibody therapy has been associated with poorer responses. The interval varied among the different studies, ranging between 9 months, 37 12 months, 41, 42, 56, 63 and up to 2 years. 45 Older age, 42,75 higher lactate dehydrogenase values, 75 IgA deficiency, 58 lymphopenia, 71 male sex, 42 and presence of immunoparesis, 31 have been associated with lower antibody response. Among those with solid cancers, cytotoxic chemotherapy is reported to be associated with poorer antibody response compared with immune checkpoint inhibitor (pembrolizumab, ipilimumab, nivolumab and atezolizumab) and endocrine therapy. 24, 25, 29, 46, 48, 54, 57, 74, 77 Patients on tyrosine kinase inhibitors (TKIs) (imatinib, dasatinib, nilotinib, ponatinib, and bosutinib) and those who underwent autologous or allogeneic hematopoietic stem cell transplantation (HSCT) showed high numerical humoral responses to vaccination. 53 However, significantly lower seroconversion rates have also been noted in patients who received HSCT and CAR-T therapy. 74 

There are fewer studies on T-cell responses following COVID-19 vaccination in patients with cancer. A UK prospective study of 151 patients with solid and haematological cancer found that a lower proportion of patients elicited a T-cell response following one dose of the BNT162b2/ Pfizer vaccine: 71% and 50% of patients with solid or haematological cancer, respectively, compared with 82% of healthy controls. 55 A low T-cell response was also found in a study from Denmark, where 46% and 45% of patients with solid or haematological cancer, respectively, elicited a T-cell response. Most (76%) of the seronegative patients did not elicit a T-cell response, and low T-cell responses were significantly associated with steroid use for immunosuppression in cancer. 34 In contrast to the antibody responses, these two studies found no significant difference between solid and haematological cancers regarding T-cell response to vaccination.

An Austrian study that compared humoral and cellular immune responses to mRNA vaccines between 86 patients with cancer and 44 control participants found that although humoral responses were significantly lower in patients with cancer versus controls, there was no statistically significant difference between the two groups regarding cellular immune response. 50 Furthermore, cancer patients were found to have discordant humoral and cellular immune responses, where those who were on active treatment showed no humoral response but a positive cellular immune response, or, conversely, absence of both facets of the immune response. A higher proportion of patients with cancer were found to generate a specific CD4 þ or CD8 þ T cell immunity in response to the mRNA-1273/ Moderna vaccine (73.2%) than to the BNT162b2/Pfizer vaccine (54.8%).

Of note, T-cell-mediated vaccine approaches against SARS-CoV-2 are under clinical investigation for patients with B-cell immune deficiencies (e.g., NCT04954469). 78 

Few studies have investigated vaccine effectiveness and breakthrough infections in patients with cancer. In a large study of 1 503 patients with solid and haematological cancer, followed-up for a median of 44 months, 1.5% of all patients with cancer developed symptoms and/or reverse transcription-polymerase chain reactionpositive COVID-19; with rates of 5% after a single dose and 0.4% after two doses of the vaccine. 43 The study included participants who received the BNT162b2/Pfizer, mRNA-1273/Moderna and ChAdOx1 (Oxford-AstraZeneca) vaccines, and found a significantly higher overall death rate in the first two months post-first dose in those who received only a single dose. 43 A study of 364 patients with solid and haematological cancers who received the BBIBP CorV (Sinopharm) vaccine found five break through infections, four of which occurred in the first month, with no hospitalizations or deaths during a three-month follow-up period. 27 Other study findings include: an infection rate of 10 out of 320 patients with multiple myeloma vaccinated with the BNT162b2/Pfizer and mRNA-1273/Moderna vaccines, 76 

Among 154 Israeli patients with solid cancer given two doses of the BNT162b2/ Pfizer vaccine, antibody responses were seen to wane after a few months. 77 Of those who seroconverted after one and/or two doses of the vaccine, 15% became seronegative by 6 months. The overall seropositivity at 6 months was 79%, and at the end of the 6-month follow-up period, none of the initially seronegative patients became seropositive. The decrease in seropositivity rates and antibody titres were similar between patients and healthy controls. 77 A third vaccine dose has been proposed as a solution to increase seroconversion rates in patients who did not seroconvert following full (double-dose) vaccination and to combat waning immunity. A study investigating antibody persistence in patients with chronic lymphocytic leukaemia (CLL), at a median of 100 days following second dose of BNT162b2/Pfizer vaccine, found antibody decay to be comparable to healthy controls. 69 On 12 80 A few studies have assessed the immunogenicity of an additional dose of vaccine in patients with cancer. Among a cohort of 52 US patients with solid cancer on active cytotoxic cancer therapy who received the BNT162b2/Pfizer vaccine, a three-fold rise in neutralizing antibody titre was seen following a third vaccine dose, without an improvement in the T-cell response. 66 In 49 US patients with haematological cancer, who were initially vaccinated with the BNT162b2/Pfizer, mRNA-1273/Moderna or Janssen Ad26.COV2.S vaccines, the use of a homologous (33%) or heterologous (67%) additional booster dose resulted in 55% of those who were seronegative after two doses to seroconvert. 39 Importantly, 35% did not respond to initial full vaccination, and remained unresponsive to the additional third dose; no significant associations were found between immunogenicity of the additional dose and type of haematological cancer, type of vaccine pairing (i.e., homologous versus heterologous), or the use of malignancy-target therapies. 39 Similar observations were made in a study of 43 French patients with haematological cancer who were vaccinated with the BNT162b2/Pfizer vaccine; 42% were seronegative before administration of a third dose and all of these patients remained unresponsive following the third dose. 64 Of the patients already seropositive before the third dose, 92% had an increased antibody titre following the third dose. Thirtysix percent of the patients were double-negative (i.e., seronegative and no demonstrable cellular immune response) before the third dose and 23% remained double-negative following the third dose. The increased antibody response following the third dose was seen in patients who had not received anti-CD20 antibody treatment in the past year, whilst the increase in T-cell response was seen in those who were not on active chemotherapy. 64 Immunogenicity and effectiveness of COVID-19 vaccines in specific haematological malignancies Disease-associated immune dysfunction and treatment-related immunosuppression are assumed to cause poor immunogenicity with COVID-19 vaccination, particularly in B lymphoid malignancies.

Among patients with CLL, efficacy of the BNT162b2/Pfizer vaccine was found to be markedly reduced. 42 In 167 patients with CLL, who were fully vaccinated with two BNT162b2/Pfizer doses, an antibody response was elicited in only 39.5% of patients. 42 The humoral response rate was 80% in those who had completed treatment and were in remission, 55% in those who were treatment-naive for CLL, and 16% in those on active treatment. Being female, relatively young, having serum IgG levels >550 mg/dL and IgM levels >40 mg/dL, and currently not receiving active treatment, were associated with better antibody responses to COVID-19 vaccination. 42 Another study found poor persistence of antibody titres at 100 days in patients with CLL, particularly among those who were female, were receiving ongoing therapy, had adverse effects to vaccination, and had low IgM antibody levels following the first dose. 69 Treatment with BTKi or venetoclax, with or without anti-CD20 antibodies, significantly impaired antibody responses. 42 Thus, administering the second dose at an earlier interval than 10-12 weeks, providing a booster third dose, and continuing non-pharmacological methods, have been recommended. 42 A subsequent study of 299 patients with CLL reported a detectable antibody response after the first dose of BNT162b2/Pfizer and ChAdOx1 (Oxford-AstraZeneca) vaccines in 34% of patients (compared with 94% of controls). 58 This response rate rose to 75% of patients versus 100% of controls following the second dose, however, antibody titres were 74-fold lower in patients with CLL. IgA deficiency was shown to be associated with poor antibody response, even after the second dose. 58

In patients with multiple myeloma (MM), the seroconversion rate following a first dose of the BNT162b2/Pfizer or ChAdOx1 (Oxford-AstraZeneca) vaccines was 56%, and lower seropositivity rates were found if the MM was active, there was immunoparesis, or if the patients were on active treatment. 31 An interim analysis of 48 elderly patients (median age, 83 years) in a similar study showed poor immune response compared with controls. 72 In a subsequent analysis of the same trial, including 276 patients with MM, smouldering myeloma and monoclonal gammopathy of undetermined significance, neutralizing antibody production was found to be lower in patients with MM compared with 226 healthy controls. 71 Another study found 55% of patients with MM to have no or partial antibody response to vaccination, 68 whilst in a separate cohort, the response rate was 76% among patients with MM versus 98% in healthy adults. 28 A large-scale study of 320 patients with MM found a seroconversion rate of 84% versus 100% in the control group, with significantly lower antibody titres in those who had received MM treatment compared with those who had not. 76 

Among 162 patients with lymphoma, the seroconversion rate following double-dose BNT162b2/Pfizer vaccination was 51%. 41 A similar rate of serological response was demonstrated in another study that included 149 patients with B-cell (B)-non-Hodgkin lymphoma (NHL). 60 A study from Greece that included 132 patients with CLL, 53 with NHL and 22 with Hodgkin lymphoma (HL) also showed poor antibody response following BNT162b2/Pfizer vaccination compared with 214 matched healthy controls. 70 Poor responses were associated with active lymphoma, being on active treatment and anti-CD20 antibody therapy in the 12 months preceding vaccination. 41, 60 The seropositivity rates increased with increasing interval from the anti-CD20 antibody therapy: 3% when administered within 45 days, rising to 80% if administered !1 year prior to vaccination. 41 A similar association with interval between the last anti-CD20 treatment and vaccination has been found in subsequent studies. 37, 63 Further, lymphocyte count at the time of vaccination !0.9 Â 10 3 /lL was also a predictor of positive serological response on multivariate analysis. 60 Among 67 patients with lymphoma, no significant difference was seen in antibody response between lymphoma types. 45 In contrast, a few studies have shown differences in humoral response based on lymphoma type. For example, patients with HL showed superior humoral responses versus CLL/NHL subgroups in a study from Greece. 70 The median time between last exposure to anti-CD20 antibody treatment and the attainment of positive serology was significantly longer in patients with indolent B-NHL than with aggressive B-NHL (36 versus 19.8 months). Response rates over time since last anti-CD20 antibody treatment exposure remained lower in patients with indolent B-NHL compared with those in patients with aggressive B-NHL. 60 Potential side-effect profile of COVID-19 vaccines in patients with cancer

The side-effect profile of the currently authorized vaccines is very similar between patients with haematological and solid cancer and the general public. A reported exception is significantly higher rate of pain at the injection site, stated in one study to be more severe in patients with B-NHL compared with healthy controls. 60 The majority of patients with cancer only experience mild to moderate adverse effects. Among patients with cancer, the most common local adverse effect following BNT162b2/Pfizer vaccination is pain at the injection site (reported in 19-69% of patients with cancer), 30, 38, 47, 48 whilst the most common systemic adverse effects are fatigue (24%) and myalgia/arthralgia/headache (7-18%). 38, 47, 48 A similar side-effect profile has been found in patients with cancer who received the BBIBP CorV (Sinopharm) vaccine (with the exception that fever (32%) was the most common systemic adverse effect), 27 and the CoronaVac (Sinovac Life Sciences) vaccine. 46 In a study of patients with B-NHL, the rate of side effects reported with the BNT162b2/Pfizer vaccination was 51%, 60 and 2.5% of patients reported transient lymphadenopathy.

According to the US Centers for Disease Control and Prevention, lymphadenopathy following administration of the BNT162b2/ Pfizer vaccine may occur within 2 to 4 days and last for an average of 10 days. 81 New onset lymphadenopathy in the cervical and/ or axillary regions, detected clinically or radiologically (by mammography, ultrasound, or fluorodeoxyglucose-positron emission tomography), have been reported following COVID-19 vaccination. 38,82 Lymphadenopathy may occur 2-13 days following vaccination, on the same side as the arm on which the vaccine was given. In most cases, no additional imaging is needed, but should be considered if the swelling persists or there are other symptoms. Understandably, for patients with lymphoma who developed lymph node enlargement as a sign of their cancer, any enlargement may cause concern. In addition, subclinical, radiologically detected lymphadenopathy may also be a cause of concern as a potential sign of metastasis in patients undergoing routine screening following previously treated cancer. 83 Other considerations in fully vaccinated patients with cancer Due to the high risk of serious breakthrough SARS-CoV-2 infections, it is imperative that household contacts and caregivers of cancer patients are fully vaccinated and non-pharmacological protective measures, such as wearing face masks, social distancing and thorough hand washing, are strictly adhered to by patients, caregivers, and family members.

Coronavirus disease 2019 (COVID-19) has significant adverse clinical, laboratory and general effects among patients with cancers. Vaccination is an important preventive measure for patients with solid and haematological malignancies against developing severe COVID-19. Immunogenicity (both humoral and cellular immune responses) of vaccines in patients with cancer is lower compared with healthy individuals. Furthermore, humoral immune responses are inferior in those with haematological versus solid cancers. Patient-, disease-, and treatment-related factors that are associated with poorer vaccine responses should be identified and corrected or mitigated when possible. Consideration should be given to offering patients with cancer a second dose of the COVID-19 vaccine at a shorter interval than in healthy individuals. Patients with cancer warrant a third vaccine dose and must be prioritized in vaccination schedules. The adverse-effect profile of vaccines in patients with cancer is comparable to that in healthy individuals.

Weekly epidemiological update on COVID-19

Atypical presentations of COVID-19

Gastrointestinal manifestations in COVID-19

Neurological manifestations in COVID-19: a narrative review

Hematological abnormalities in COVID-19: a narrative review

Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Favipiravir in Covid-19

Remdesivir and Covid-19

COVID-19 vaccine landscape

The delta variant of SARS-CoV-2: the current global scourge

SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 23

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Fast-spreading COVID variant can elude immune responses

Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant

Seroconversion after influenza vaccination in patients with lung cancer

Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario, Canada

Serological immune responses to influenza vaccine in patients with colorectal cancer

Immunogenicity of a two-dose regime of varicella vaccine in children with cancers

Immunogenicity of hepatitis A vaccine in children with cancer

Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Efficacy of the mRNA-based BNT162b2 COVID-19 vaccine in patients with solid malignancies treated with anti-neoplastic drugs

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv

Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy

Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Disease-and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine

Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19þ B-lymphocyte count and anti-CD38 treatment

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

Serological response to COVID-19 vaccination in patients with cancer older than 80 years

Serologic response to mRNA COVID-19 vaccination in lymphoma patients

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Antibody response to COVID-19 vaccination in adults with hematologic malignant disease

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: a monocentric experience

Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy

Evaluation of antibody responses to COVID-19 vaccines among solid tumor and hematologic patients

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Seroconversion rates following COVID-19 vaccination among patients with cancer

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Six month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors

Study to Prevent COVID-19 Infection in Adults With

Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals

report: Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination

Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 vaccine reactions & adverse events

COVID-19 vaccination-associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women

COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET/CT

The authors declare that there is no conflict of interest.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Suranjith L Seneviratne https://orcid.org/ 0000-0002-6548-5673